Overview
Rheumatoid lung disease encompasses pulmonary manifestations associated with rheumatoid conditions, including interstitial lung disease and granulomatous lesions, often occurring in the absence of overt joint involvement 3.Diagnosis
Presence of high titers of rheumatoid factor 3
Radiological evidence of interstitial pulmonary fibrosis or granulomatous lesions 3
Exclusion of other causes through comprehensive imaging (CT, MRI) and pulmonary function tests 3
Identification of multisystem involvement, particularly in complex cases 1Management
First-line treatments often include disease-modifying antirheumatic drugs (DMARDs); specific mention of penicillamine as a slow-acting antirheumatic drug, though dosing specifics are not provided 2
Adjunctive management may involve immunosuppressive agents targeting systemic manifestations 3
Supportive care for respiratory complications, such as oxygen therapy and pulmonary rehabilitation, as indicated 3Special Populations
Pregnancy: Limited data; management should focus on minimizing disease activity while avoiding teratogenic risks 2
Elderly: Consideration of comorbidities and potential drug interactions; cautious use of penicillamine due to renal risks 2Key Recommendations
Evaluate for high rheumatoid factor titers and multisystem involvement in suspected cases (Evidence: Weak 31)
Utilize imaging studies (CT, MRI) to diagnose interstitial lung disease and granulomatous lesions (Evidence: Weak 3)
Consider penicillamine as a potential slow-acting antirheumatic drug in treatment regimens, weighing risks and benefits carefully (Evidence: Expert opinion 2)References
1 Yan R, Jin YB, Li XR, Luo L, Liu XM, He J. Clinical characteristics of rheumatic disease-associated hypophysitis: A case series and review of literature. Medicine 2022. link
2 Thrift EG, Lewis B. Penicillamine in rheumatoid disease. Australian family physician 1983. link
3 Frayha R, Ayyash R, Gehshan A, Gemayel N. Rheumatoid disease without arthritis. The Johns Hopkins medical journal 1976. link